Could Federal Preemption Blow Up a $289M Roundup Verdict on Appeal?
California's First District Court of Appeal ordered additional briefing on Monsanto's defense of federal preemption—an issue that could have wide ramifications for all Roundup lawsuits. California Attorney General Xavier Becerra filed an amicus brief supporting plaintiffs' claims against federal preemption.
February 12, 2020 at 05:48 PM
6 minute read
The original version of this story was published on The Recorder
In an appeal that could have wide-ranging ramifications for thousands of Roundup lawsuits, lawyers on both sides of a $289 million verdict now on appeal filed supplemental briefs Tuesday addressing whether federal law preempted claims that Monsanto Co. failed to warn about its herbicide's health risks.
The supplemental briefs, which also included an amicus brief, filed by California Attorney General Xavier Becerra, come in the appeal of a $289 million verdict in 2018 to plaintiff Dewayne Lee Johnson, who alleged Roundup caused his non-Hodgkin lymphoma. California's First District Court of Appeal, which has indicated that it could set oral argument for March or April, asked both sides to file supplemental briefs responding to three questions that addressed whether the U.S. Supreme Court's decisions on federal preemption, such as Wyeth v. Levine, applied to Roundup.
Monsanto, now owned by Bayer AG, insisted in its brief that, under Wyeth, there was "clear evidence" the EPA would not have allowed it to change Roundup's label to warn of cancer risks.
"Plaintiff's state-law failure-to-warn claims are preempted because there is 'clear evidence' that EPA, having been fully informed, would have rejected Monsanto's request to add the label warning that state law here purportedly requires," wrote David Axelrad, of Burbank, California's Horvitz & Levy, along with attorneys at Bryan Cave Leighton Paisner. As a result, he wrote, "it would be 'impossible' for Monsanto to comply with both federal law and the state-law duty to warn theory on which the verdict rests."
Plaintiffs attorney Curtis Hoke, in a separate brief, said that no such "clear evidence" existed.
"It never asked for a label change, it withheld key data, it failed to test its product, and it marshalled enormous resources and influence to prevent a label change," Hoke, of the Miller Firm in Orange, Virginia, wrote about Monsanto. "The EPA has also never formally rejected a request to add a cancer warning to a Roundup label on the basis that NHL is a potential risk of Roundup."
The Johnson verdict, later reduced to $78.5 million, was the first of three against Monsanto, which faces 42,700 lawsuits over Roundup. Juries last year awarded verdicts of $2 billion and $80 million. Bayer has raised federal preemption in all three appeals. In the $80 million verdict, Bayer filed its brief on Dec. 13 before the U.S. Court of Appeals for the Ninth Circuit, and, in the $2 billion award, before the First District Court of Appeal on Feb. 7.
On Jan. 21, the First District Court of Appeal, citing recent affirmations by the EPA on the safety of Roundup ingredient glyphosate, and the U.S. Supreme Court's preemption holdings in Merck Sharp & Dohme v. Albrecht and Wyeth v. Levine, asked lawyers to answer three questions:
- Should Wyeth be extended to the FIFRA [Federal Insecticide, Fungicide, and Rodenticide Act], such that a court should determine whether there is clear evidence the EPA would not have approved a change to the labels of Monsanto's glyphosate-based products?
- Assuming that Wyeth applies, is this a determination that should be made by this court in the first instance or on remand in the trial court? And whichever court makes the determination, how should it be made?
- If a court were to determine that FIFRA preempts Johnson's failure-to-warn causes of action under Wyeth, but not Johnson's design-defect cause of action, what effect, if any, would that have on the jury's verdict?
In its supplemental brief, Bayer argued that Wyeth's "impossibility" standard governed the case, that the First District Court of Appeal should decide for preemption and order a new trial given that other claims of defective design were intertwined with failure-to-warn allegations. Bayer's brief relied on the EPA's position since 1991, most recently reaffirmed last month, that glyphosate does not cause cancer.
"EPA's approval of a label in the course of registering a product compels the use of that approved label, without deviation," Axelrad wrote. "Monsanto could not lawfully add a cancer warning to Roundup's label at all without prior EPA approval."
Additionally, he wrote, Wyeth, which involved a prescription drug, addressed "longstanding preemption principles" that are not limited to the Food, Drug, and Cosmetic Act.
"This court should thus apply the 'clear evidence' standard to determine whether federal law prohibits a pesticide manufacturer from adding a warning required by state law, just as the Supreme Court applied the standard when determining whether federal law prohibited a drug manufacturer from adding a warning required by state law," Axelrad wrote.
Johnson's lawyers, who also include those at Los Angeles-based Baum, Hedlund, Aristei & Goldman and San Francisco's Audet & Partners, wrote that the First District Court of Appeal should decide against federal preemption issue but, should it side with Bayer, exclude design defect claims, which are about the design of the product and not the labeling.
The verdict, Hoke wrote, should stand.
Moreover, unlike the statute at issue in Wyeth and Merck, FIFRA did not preempt the claims in Roundup, because it "expressly contemplates that states can disallow what EPA permits," he wrote.
"A California jury can therefore find that a product is misbranded under FIFRA even where the EPA does not," Hoke wrote. "This court should decline Monsanto's request to create a new rule that would bestow blanket immunity upon manufacturers of registered pesticides."
Both Hoke and the state, in its amicus brief, noted that the FIFRA would not preempt failure-to-warn claims for the additional reason that cancer warnings could be on store signs, not Roundup's labels.
The state, in its brief, emphasized its police powers under California's Safe Drinking Water and Toxic Enforcement Act of 1986, or Proposition 65, which classifies glyphosate as carcinogenic.
"The fact is EPA's failure to regulate glyphosate doesn't excuse Monsanto from liability or preempt California from requiring that consumers be informed of the risks of cancer-causing products," Becerra said in a statement on Wednesday. "California protects its residents from dangerous pesticides, and we shouldn't be forced to put our heads in the sand simply because the EPA won't do its job."
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllLitigators of the Week: After a 74-Day Trial, Shook Fends Off Claims From Artist’s Heirs Against UMB Bank
An ‘Indiana Jones Moment’: Mayer Brown’s John Nadolenco and Kelly Kramer on the 10-Year Legal Saga of the Bahia Emerald
‘It's Your Funeral’: Avoiding Doing Damage to Your Client’s Case With Uncivil Behavior
Law Firms Mentioned
Trending Stories
Who Got The Work
Michael G. Bongiorno, Andrew Scott Dulberg and Elizabeth E. Driscoll from Wilmer Cutler Pickering Hale and Dorr have stepped in to represent Symbotic Inc., an A.I.-enabled technology platform that focuses on increasing supply chain efficiency, and other defendants in a pending shareholder derivative lawsuit. The case, filed Oct. 2 in Massachusetts District Court by the Brown Law Firm on behalf of Stephen Austen, accuses certain officers and directors of misleading investors in regard to Symbotic's potential for margin growth by failing to disclose that the company was not equipped to timely deploy its systems or manage expenses through project delays. The case, assigned to U.S. District Judge Nathaniel M. Gorton, is 1:24-cv-12522, Austen v. Cohen et al.
Who Got The Work
Edmund Polubinski and Marie Killmond of Davis Polk & Wardwell have entered appearances for data platform software development company MongoDB and other defendants in a pending shareholder derivative lawsuit. The action, filed Oct. 7 in New York Southern District Court by the Brown Law Firm, accuses the company's directors and/or officers of falsely expressing confidence in the company’s restructuring of its sales incentive plan and downplaying the severity of decreases in its upfront commitments. The case is 1:24-cv-07594, Roy v. Ittycheria et al.
Who Got The Work
Amy O. Bruchs and Kurt F. Ellison of Michael Best & Friedrich have entered appearances for Epic Systems Corp. in a pending employment discrimination lawsuit. The suit was filed Sept. 7 in Wisconsin Western District Court by Levine Eisberner LLC and Siri & Glimstad on behalf of a project manager who claims that he was wrongfully terminated after applying for a religious exemption to the defendant's COVID-19 vaccine mandate. The case, assigned to U.S. Magistrate Judge Anita Marie Boor, is 3:24-cv-00630, Secker, Nathan v. Epic Systems Corporation.
Who Got The Work
David X. Sullivan, Thomas J. Finn and Gregory A. Hall from McCarter & English have entered appearances for Sunrun Installation Services in a pending civil rights lawsuit. The complaint was filed Sept. 4 in Connecticut District Court by attorney Robert M. Berke on behalf of former employee George Edward Steins, who was arrested and charged with employing an unregistered home improvement salesperson. The complaint alleges that had Sunrun informed the Connecticut Department of Consumer Protection that the plaintiff's employment had ended in 2017 and that he no longer held Sunrun's home improvement contractor license, he would not have been hit with charges, which were dismissed in May 2024. The case, assigned to U.S. District Judge Jeffrey A. Meyer, is 3:24-cv-01423, Steins v. Sunrun, Inc. et al.
Who Got The Work
Greenberg Traurig shareholder Joshua L. Raskin has entered an appearance for boohoo.com UK Ltd. in a pending patent infringement lawsuit. The suit, filed Sept. 3 in Texas Eastern District Court by Rozier Hardt McDonough on behalf of Alto Dynamics, asserts five patents related to an online shopping platform. The case, assigned to U.S. District Judge Rodney Gilstrap, is 2:24-cv-00719, Alto Dynamics, LLC v. boohoo.com UK Limited.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250